Appendix 4E and Annual Report
Filed with ASX · · 61 pages · English
Summary by 6ix AI
The report indicates a significant decline in revenues from ordinary activities and an increase in losses attributable to the owners of Xenitra Limited compared to the previous year. No dividends were declared or paid during the current financial period, reflecting the company's focus on restructuring and transformation efforts. The report also highlights a strategic reset and corporate transformation aimed at improving operational efficiency and profitability moving forward.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Xenitra
- Xenitra Raises $1.5m to Accelerate High-Margin Sales Growth
- $5m Offtake Agreement Expands OTC-Medicine Business
- $12M offtake agreement with leading OTC-pharmaceutical
- $1.1m in OPAL-Tokenised Product Sales in First 7 Weeks
- XEN Appointed as Exclusive Biomiq Skincare China Distributor
Later from Xenitra
All Xenitra news releasesFollow Xenitra into a list and get an email when it puts out news.
Follow Xenitra